Seeking Alpha

CHMP recommends EMA approval of biosimilar insulin

  • Europe's Committee for Medicinal Products for Human Use (CHMP) recommends that the European Medicines Agency (EMA) approve Eli Lilly (LLY) and Beohringer Ingelheim's investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. It is the first biosimilar insulin recommended for E.U. approval. It has the same amino acid sequence as Sanofi's Lantus (insulin glargine).
  • The European Commission's final decision is expected in ~2 months.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: